China-based EOC Pharma Group has announced a strategic partnership with fellow country siRNA firm, Nanopeptide (Qingdao) Biotechnology Ltd., to delve into the research and development of small nucleic acid drugs within the cardiovascular field.
Agreement Terms and Regional Rights
Under the terms of the agreement, Nanopeptide has granted EOC Pharma Group development, manufacturing, and commercialization rights for its ANGPTL3 and Lp(a) siRNA drugs in Greater China and Southeast Asia. This partnership signifies a significant step forward in the advancement of siRNA therapeutics for cardiovascular diseases.
Financial Commitments and Collaboration Scope
EOC Pharma Group is committed to making an undisclosed amount of upfront payments, milestone payments, and sales commissions to Nanopeptide. The collaboration aims to leverage the expertise of both companies to bring innovative siRNA drugs to market, potentially transforming treatment options for patients with cardiovascular conditions.-Fineline Info & Tech
